Oxford Biotherapeutics Relocates Its UK Base to the Oxford Science Park, Aiming to Accelerate the Development of Immuno-oncology and ADC-based Cancer Treatments
Thursday, October 12, 2023
Oxford BioTherapeutics Ltd. (OBT), a clinical-stage oncology company specializing in immuno-oncology and antibody-drug conjugate (ADC)-based therapies, has relocated its UK headquarters to The Schrodinger Building within The Oxford Science Park. The new facilities include state-of-the-art office and custom laboratory spaces, enhancing OBT's capabilities in target discovery and drug development.
This strategic move positions OBT at the center of the rapidly growing Oxford biotech ecosystem, providing access to world-class expertise and talent. OBT joins other innovative biotech companies and research institutes in making this transition, including the recent expansion of the Ellison Institute for Transformative Medicine in Oxford. OBT's new headquarters allows it to leverage the local network of high-quality talent, benefiting from its proximity to the University of Oxford.
Dr. Christian Rohlff, the Chief Executive Officer of Oxford BioTherapeutics, expressed his excitement, saying, "We are delighted to move to The Oxford Science Park and collaborate with leading biotech firms in the UK. This move represents a significant milestone in our growth, driven by our proprietary OGAP® discovery platform and substantial progress in clinical and pre-clinical programs with pharmaceutical partners. Our expanded, cutting-edge R&D facilities will empower us to further develop our leading target discovery capabilities and accelerate our efforts to create innovative immunotherapies for people affected by cancer."
